ϩ/hi and granulocytic/polymorphonuclear-leukocyte-like Ly6G ϩ/hi Ly6C ϩ/Ϫ/lo , use differential suppressive mechanisms to inhibit T cells (12, 13) . MDSC inhibition of B-cell responses is studied rarely, if at all.
M
yeloid-derived suppressor cells (MDSCs) inhibit the generation and/or effector activities of antitumor T-cell responses (1, 2) . Limited reports indicate MDSC regulation of autoimmunity (3) and selected viral infections (4-7), including only recently, retroviral infections and murine and human AIDS (8) (9) (10) (11) . Murine MDSCs are relatively immature and heterogeneous, but all express Gr-1 and CD11b. Two subsets, monocytic Ly6G ϩ/Ϫ/lo
Ly6C
ϩ/hi and granulocytic/polymorphonuclear-leukocyte-like Ly6G ϩ/hi Ly6C ϩ/Ϫ/lo , use differential suppressive mechanisms to inhibit T cells (12, 13) . MDSC inhibition of B-cell responses is studied rarely, if at all.
Retroviruses are adept at co-opting immunoregulatory mechanisms. Human immunodeficiency virus type 1/simian immunodeficiency virus induction of PD-1 downregulates T effector cells (14, 15) , and murine Friend retrovirus infection-induced PD-1 and Tim-3 affect pathogenesis and retroviral loads (16, 17) , sometimes with "functionless" T cells occurring (14, 15) . Viral infections can also induce CD4 ϩ FoxP3 ϩ regulatory T (Treg) cells (18) , including in LP-BM5 murine retroviral pathogenesis (19) (20) (21) . By 5 weeks postinfection (wpi), LP-BM5 causes profound immunodeficiency, with increased susceptibility to "opportunistic" infections and B-cell lymphomas (22, 23) . Immunodeficiency requires "pathogenic" CD4
ϩ T-effector cell expression of CD154 and ligation of CD40 (22, 24, 25) , and PD-1/PD-L1 and IL-10 downregulate effector T-cell activity (21, 26) .
A CD11b ϩ FcR␥III/II ϩ myeloid cell subset expands during LP-BM5 pathogenesis (26, 27) . We recently defined these monocytic MDSCs as Gr-1 ϩ Ly6C ϩ/hi Ly6G ϩ/Ϫ/low CD11b ϩ with strong ex vivo inhibition of T-and B-cell responses used to measure LP-BM5-induced immunodeficiency (10) . This robust direct MDSCinduced inhibition of B-cell responsiveness is novel for murine retrovirus-induced immunosuppression, if not generally. Also, a new negative-checkpoint regulatory ligand, VISTA (V-domain Ig suppressor of T-cell activation) (28) (29) (30) , also designated PD-1H (31) , with homology to PD-L1 has been defined. VISTA can be highly upregulated on myeloid-derived cells and can inhibit T-cell responses in autoimmunity and antitumor immunity in a nonredundant manner with PD-L1 (28) .
At 5 wpi with LP-BM5, regarding cell surface VISTA expression, the percentage of VISTA ϩ spleen cells had not expanded but VISTA mean fluorescence intensity (MFI) increased and the shape of the positive peak changed, consistent with the dominance of CD4 T-cell-expressed VISTA in uninfected B6 mice (28) and with CD11b ϩ VISTA ϩ cell expansion. Comparison of cells from wild-type (WT), iNOS Ϫ/Ϫ , and VISTA Ϫ/Ϫ B6 mice (32) at 5 wpi confirmed VISTA and CD11b coexpression by the highly enriched monocytic Ly6C ϩ MDSC population we have previously described (10) , as depicted in the representative experiment in Fig. 1 (consistent with the average MFI and percent positivity over three experiments [legend to Fig. 1] ). Of note, there was minimal contamination with other cells, particularly CD4
ϩ Treg cells (legend to Fig. 1 ). Interestingly, similar monocytic MDSCs could be isolated from the spleens of uninfected mice. These MDSCs expressed levels of VISTA approaching (and, over three repeat experiments, not significantly statistically significantly different from) that of their counterparts from infected mice-with respect to both the percent positive and the MFI (legend to Fig. 1) . However, such MDSCs from uninfected mice were much less frequent in total cell numbers per spleen and, even compared on a per-cell basis, displayed substantially less suppressive activity-resulting in about 12-fold less MDSC suppressive function than MDSCs from infected mice (legend to Fig. 1 ).
The possible mechanistic involvement of VISTA was compared to the known differential role of inducible nitric oxide synthase (iNOS)/nitric oxide (NO) in MDSC-mediated suppression ( Fig. 2A and B) . However, MDSC-mediated suppression of uninfected WT T cells was essentially completely dependent on iNOS/NO, as shown with the iNOS inhibitor N G -monomethyl L-arginine (L-NMMA). For B-cell responsiveness, L-NMMA blocked MDSC-mediated suppression by ϳ50% (range, 40 to 65%), as previously shown (10), but an anti-VISTA monoclonal antibody (MAb) blocked WT MDSCmediated suppression of only B-cell (by ϳ50%), and not Tcell, responsiveness ( Fig. 2A and B) . We found the range of anti-VISTA MAb blocking centered around 65%, but a delta of ϳ55%, by subtracting control hamster immunoglobulin effects (Fig. 2C) , a level consistent with the reduced suppression observed with VISTA Ϫ/Ϫ MDSCs (see Fig. 4 ). Thus, VISTA appeared to serve differentially, relative to iNOS/NO, for MDSC-mediated suppression of T-cell versus B-cell responses. With VISTA Ϫ/Ϫ responder cells (Fig. 2D) , the anti-VISTA MAb also showed highly significant (P ϭ 0.003) but partial specific blocking, confirming that VISTA blocking was directed to the MDSCs; for clarity, follow-up experiments employed VISTA Ϫ/Ϫ responders. In experiments not shown (three of three), the anti-VISTA MAb also blocked the suppression of B-cell responses by iNOS Ϫ/Ϫ MDSCs-and, as expected, the Combined treatment experiments were conducted. We first employed MDSCs of WT versus VISTA Ϫ/Ϫ origin in the presence of the iNOS/NO inhibitor L-NMMA. As expected, suppression of B-cell responsiveness by WT MDSCs was partially blocked by either the anti-VISTA MAb or L-NMMA (Fig. 4A,  top) . But in the same experiment, MDSCs of VISTA Ϫ/Ϫ origin suppressed B-cell responsiveness in a manner that was blocked only by L-NMMA (Fig. 4A, bottom) . And the extent of blocking was then essentially 100%, suggesting that the retained iNOS/NO pathway was the sole major suppressive mechanism. As a follow-up approach, WT MDSCs were treated with the anti-VISTA MAb, L-NMMA, or both reagents (Fig. 4B) . Only when the involvement of both VISTA and iNOS/NO was interfered with was there an essentially complete blockade of suppression (Fig. 4B) . Considering also repeat experimentation, additive, if not synergistic, blocking by simultaneously interfering with iNOS/NO and VISTA corroborated these two primary independent mechanisms of MDSC-mediated suppression of B-cell responses.
To independently assess the ability of VISTA to inhibit B-cell responsiveness, we employed a VISTA-Ig chimeric fusion protein (28) (legend to Fig. 4) . As shown in the representative results in Fig. 4) , such inhibition was observed upon stimulation either with anti-CD40 antibody plus interleukin-4 (IL-4) or with lipopolysaccharide (LPS), complete titration could be achieved, and there was no consistent difference in susceptibility between WT and VISTA Ϫ/Ϫ responder B cells to blocking by VISTA-Ig.
In conclusion, we describe here for the first time, to our knowledge, the involvement of the novel negative-checkpoint regulator VISTA in MDSC-mediated suppression-in particular, of B-cell responsiveness. Our recent finding (10) that LP-BM5-augmented MDSC-mediated suppression depends on neither PD-L1 nor PD-1 further underscores the uniqueness of VISTA-related function versus its closest relative by sequence homology, PD-L1 (28, 30) . The differential involvement of VISTA in the suppression of B-cell versus T-cell responsiveness by the same population of monocytic MDSCs raises the possibility of functional/phenotypic MDSC subpopulations. In addition, the inability to block MDSC inhibition of T-cell polyclonal responses by anti-VISTA MAb treatment here is to be contrasted with previous results demonstrating substantial effects on T-cell function by anti-VISTA MAb blockade in in vitro and in vivo assays (28, 29) . Whether this dichotomy relates to the different myeloid compartment cells studied (e.g., MDSCs here versus myeloid DCs), the differential strength of the stimulatory signal to the responder T cells, and/or differences in the experimental microenvironments from which the myeloid cells were derived is at present unclear but likely insightful. 
